[go: up one dir, main page]

AR066421A1 - Compuestos derivados de piridona - Google Patents

Compuestos derivados de piridona

Info

Publication number
AR066421A1
AR066421A1 ARP080101864A ARP080101864A AR066421A1 AR 066421 A1 AR066421 A1 AR 066421A1 AR P080101864 A ARP080101864 A AR P080101864A AR P080101864 A ARP080101864 A AR P080101864A AR 066421 A1 AR066421 A1 AR 066421A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
cycloalkyl
substituents
optionally substituted
formula
Prior art date
Application number
ARP080101864A
Other languages
English (en)
Inventor
Chiyoshi Kasahara
Hitoshi Yamazaki
Original Assignee
Astellas Pharma Inc
Wuakunaga Pharmaceuticalco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Wuakunaga Pharmaceuticalco Ltd filed Critical Astellas Pharma Inc
Publication of AR066421A1 publication Critical patent/AR066421A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se reivindican compuestos, composicion farmacéutica en base a ellos y uso del compuesto para producir una composicion farmacéutica. Los compuestos son utiles para la prevencion y tratamiento de artritis reumatoide, inflamacion intestinal, enfermedadde Crohn y psoriasis. Reivindicacion 1: Un compuesto caracterizado por la formula (1), en donde R1 es alquilo inferior, cicloalquilo o anillo hidrocarbonado aromático, cada uno de los cuales está opcionalmente sustituido con uno o mássustituyentes; R2 es un átomo de halogeno, alquilo inferior, haloalquilo inferior o alcoxi inferior; y es R3 (1) un grupo representado por la formula (2) en donde R4 es alquilo inferior, alcoxi inferior, cicloalquilo, heteroanillo aromático,heteroanillo no aromático o anillo hidrocarbonado aromático, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes; (2) un grupo representado por la formula (3) en donde R5 es alquilo inferior, cicloalquilo, anillohidrocarbonado aromático) heteroanillo aromático o heteroanillo no aromático, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes; (3) un grupo representado por la formula (4) en donde R6 es alquilo inferior,cicloalquilo, anillo hidrocarbonado aromático o heteroanillo no aromático, cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes; o (4) un grupo seleccionado de átomo de halogeno, carboxi, hidroxi y alcoxi inferior, o unade sus sales.
ARP080101864A 2007-05-03 2008-05-02 Compuestos derivados de piridona AR066421A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91584507P 2007-05-03 2007-05-03

Publications (1)

Publication Number Publication Date
AR066421A1 true AR066421A1 (es) 2009-08-19

Family

ID=39865639

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101864A AR066421A1 (es) 2007-05-03 2008-05-02 Compuestos derivados de piridona

Country Status (15)

Country Link
US (1) US8173684B2 (es)
EP (1) EP2155683B8 (es)
JP (1) JP2010526026A (es)
KR (1) KR20100016563A (es)
CN (1) CN101675034A (es)
AR (1) AR066421A1 (es)
AT (1) ATE502013T1 (es)
CA (1) CA2686091A1 (es)
DE (1) DE602008005581D1 (es)
ES (1) ES2363109T3 (es)
MX (1) MX2009011769A (es)
PL (1) PL2155683T3 (es)
PT (1) PT2155683E (es)
TW (1) TW200904421A (es)
WO (1) WO2008140066A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
CN103221395A (zh) * 2010-11-23 2013-07-24 先正达参股股份有限公司 杀虫化合物
MY188000A (en) 2011-12-28 2021-11-08 Fujifilm Corp Novel nicotinamide derivative or salt thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN104961803B (zh) * 2015-07-08 2017-11-28 中国人民解放军军事医学科学院基础医学研究所 一种治疗心肌缺血再灌注损伤的多肽药物
CN104961804B (zh) * 2015-07-08 2017-12-01 中国人民解放军军事医学科学院基础医学研究所 p38α拮抗肽突变体及其应用
JP7013453B2 (ja) * 2016-06-23 2022-01-31 ユニバーシティ・オブ・メリーランド・ボルティモア 内皮安定化及び抗炎症活性を有する非触媒基質選択的ｐ３８α特異的ＭＡＰＫ阻害剤、及びその使用方法
CN107033134B (zh) * 2017-05-03 2020-02-21 贵州大学 含吡啶盐和1,3,4-噁二唑基的双酰胺类化合物及其制备方法及应用
EP3890733A4 (en) 2018-12-07 2022-05-04 University of Maryland, Baltimore NON-ATP/CATALYTIC SITE P38 MITOGENE-ACTIVATED PROTEIN KINASE INHIBITORS
JP2022550886A (ja) * 2019-10-04 2022-12-05 アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） 新規なピリジン－２（１ｈ）オン誘導体、その調製、及び疼痛を処置するためのその使用
AU2021274475B2 (en) 2020-05-18 2024-03-21 Gen1E Lifesciences Inc. P38alpha mitogen-activated protein kinase inhibitors
US11390581B2 (en) 2020-10-29 2022-07-19 Gen1E Lifesciences Inc. Crystalline 5-(dimethylamino)-n-(4-(morpholinomethyl)phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate
CA3213095A1 (en) 2021-03-23 2022-09-29 Adam Galan Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO2006051826A1 (ja) 2004-11-10 2006-05-18 Ono Pharmaceutical Co., Ltd. 含窒素複素環化合物およびその医薬用途
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CN101268079B (zh) * 2005-09-01 2011-09-14 安斯泰来制药有限公司 用于治疗疼痛的哒嗪酮衍生物

Also Published As

Publication number Publication date
EP2155683B1 (en) 2011-03-16
DE602008005581D1 (de) 2011-04-28
ATE502013T1 (de) 2011-04-15
US8173684B2 (en) 2012-05-08
US20100063098A1 (en) 2010-03-11
ES2363109T3 (es) 2011-07-20
KR20100016563A (ko) 2010-02-12
WO2008140066A3 (en) 2008-12-31
EP2155683A2 (en) 2010-02-24
CA2686091A1 (en) 2008-11-20
JP2010526026A (ja) 2010-07-29
TW200904421A (en) 2009-02-01
EP2155683B8 (en) 2011-09-21
PL2155683T3 (pl) 2011-08-31
WO2008140066A2 (en) 2008-11-20
CN101675034A (zh) 2010-03-17
PT2155683E (pt) 2011-04-11
MX2009011769A (es) 2009-11-13

Similar Documents

Publication Publication Date Title
AR066421A1 (es) Compuestos derivados de piridona
AR061644A1 (es) Derivados de benzofurano
AR068764A1 (es) N-piperazin amidas y su uso en medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de faah.
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
EA201170096A1 (ru) Замещенные производные пиримидона
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR073136A1 (es) Compuestos de pirrol
CU20100021A7 (es) Derivado de oxopirazina y herbicida
CO5690643A2 (es) Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
ECSP11011318A (es) Derivados de benzofurano
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
AR077977A1 (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
EA201890152A1 (ru) Производные 2,3-дигидро-4h-1,3-бензоксазин-4-онов в качестве модуляторов холинергического мускаринового m1 рецептора
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
AR076008A1 (es) Derivados de hidroximetil-isoxazol moduladores de receptores gaba a, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento del alzheimer y otros trastornos cognitivos.
PE20110196A1 (es) 5-alquinil-pirimidinas
AR066606A1 (es) Compuestos de heteroarilamida pirimidona
MY169179A (en) Novel piperidine compound or salt thereof
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra

Legal Events

Date Code Title Description
FB Suspension of granting procedure